Metagenomi Therapeutics (MGX) Accumulated Depreciation (2023 - 2025)

Metagenomi Therapeutics (MGX) has 3 years of Accumulated Depreciation data on file, last reported at $16.0 million in Q4 2025.

• Accumulated Depreciation for Q4 2025 came in at $16.0 million, up 41.64% year-over-year; the trailing twelve-month figure through Dec 2025 was $16.0 million (up 41.64% YoY), and the FY2025 annual result was $16.0 million, up 41.64% from the prior year.
• Accumulated Depreciation improved to $16.0 million in Q4 2025 per MGX's latest filing, from $11.3 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $16.0 million in Q4 2025 and troughed at $6.4 million in Q4 2023.
• A 3-year average of $11.2 million and a median of $11.3 million in 2024 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2024 and 2025: Accumulated Depreciation soared 75.15% in 2024, then surged 41.64% in 2025.
• A 3-year view of Accumulated Depreciation shows it stood at $6.4 million in 2023, then soared by 75.15% to $11.3 million in 2024, then surged by 41.64% to $16.0 million in 2025.
• Business Quant data shows MGX's Accumulated Depreciation at $16.0 million in Q4 2025, $11.3 million in Q4 2024, and $6.4 million in Q4 2023.